While prior reviews have summarized NSCLC resistance mechanisms [4,14] or radionuclide therapies as independent topics [14,15], no review has comprehensively integrated amino acid transporter biology with 211At-based α-particle therapeutics. The gene discussed is SLC38A7; the disease is non-small cell lung carcinoma.